ATEA PHARMACEUTICALS INC's ticker is AVIR and the CUSIP is 04683R106. A total of 126 filers reported holding ATEA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.50 and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,998,456 | -17.4% | 666,152 | +3.0% | 0.00% | – |
| Q2 2023 | $2,418,819 | +2.4% | 646,743 | -8.3% | 0.00% | – |
| Q1 2023 | $2,361,897 | -30.9% | 705,044 | -0.8% | 0.00% | -100.0% |
| Q4 2022 | $3,419,612 | -17.1% | 710,938 | -2.0% | 0.00% | 0.0% |
| Q3 2022 | $4,127,000 | -16.1% | 725,226 | +4.6% | 0.00% | 0.0% |
| Q2 2022 | $4,921,000 | +21.7% | 693,126 | +23.8% | 0.00% | 0.0% |
| Q1 2022 | $4,043,000 | -21.4% | 560,020 | -2.7% | 0.00% | 0.0% |
| Q4 2021 | $5,143,000 | -75.2% | 575,268 | -2.7% | 0.00% | -75.0% |
| Q3 2021 | $20,733,000 | +85.5% | 591,361 | +13.6% | 0.00% | +100.0% |
| Q2 2021 | $11,179,000 | +8.3% | 520,422 | +211.3% | 0.00% | 0.0% |
| Q1 2021 | $10,321,000 | +39.6% | 167,160 | -5.5% | 0.00% | +100.0% |
| Q4 2020 | $7,391,000 | – | 176,905 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | $17,648,000 | 2.07% |
| EcoR1 Capital, LLC | 6,340,639 | $45,019,000 | 1.55% |
| CM Management, LLC | 200,000 | $1,420,000 | 1.51% |
| K2 PRINCIPAL FUND, L.P. | 1,606,059 | $11,403,000 | 1.26% |
| Cormorant Asset Management, LP | 1,547,181 | $10,985,000 | 0.83% |
| Privium Fund Management (UK) Ltd | 61,284 | $435,000 | 0.49% |
| Atom Investors LP | 30,911 | $219,000 | 0.10% |
| FEDERATED HERMES, INC. | 3,588,131 | $25,476,000 | 0.07% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 347,612 | $2,468,000 | 0.06% |
| BALYASNY ASSET MANAGEMENT L.P. | 1,799,507 | $12,777,000 | 0.04% |